期刊
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
卷 58, 期 4, 页码 2418-2421出版社
AMER SOC MICROBIOLOGY
DOI: 10.1128/AAC.01526-13
关键词
-
资金
- National Natural Science Foundation of China [30901876, 81273427]
- National Mega-project for Innovative Drugs, People's Republic of China [2012ZX09301002-001, 2012ZX09301002-005]
MRX-I is a potent oxazolidinone antibiotic against Gram-positive pathogens, including methicillin-resistant Staphylococcus aureus (MRSA), penicillin-resistant Streptococcus pneumoniae (PRSP), penicillin-intermediate S. pneumoniae (PISP), and vancomycin-resistant enterococci (VRE). In this study, the in vivo efficacy of orally administered MRX-I was evaluated using linezolid as a comparator. MRX-I showed the same or better efficacy than linezolid in both systemic and local infection models against the tested strains.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据